The DOI matches its Crossref record; 89 of the 89 references it cites were found in a registry or an index.
Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer—Shifting the paradigm
Open accessAbstract
Recent morphologic, immunohistochemical and molecular genetic studies have led to the development of a new paradigm for the pathogenesis and origin of epithelial ovarian cancer (EOC) based on a dualistic model of carcinogenesis that divides EOC into two broad categories designated type I and type II. Type I tumors are comprised of low-grade serous, low-grade endometrioid, clear cell and mucinous carcinomas and Brenner tumors. They are generally indolent, present in stage I (tumor confined to the ovary) and are characterized by specific mutations, including KRAS, BRAF, ERBB2, CTNNB1, PTEN PIK3CA, ARID1A, and PPPR1A, which target specific cell signaling pathways. Type I tumors rarely harbor TP53 and are relatively stable genetically. Type II tumors are comprised of high-grade serous, high-grade endometrioid, malignant mixed mesodermal tumors (carcinosarcomas) and undifferentiated carcinomas. They are aggressive, present in advanced stage, and have a very high frequency of TP53 mutations but rarely harbor the mutations detected in type I tumors. In addition, type II tumors have molecular alterations that perturb expression of BRCA either by mutation of the gene or by promotor methylation. A hallmark of these tumors is that they are genetically highly unstable. Recent studies strongly suggest that fallopian tube epithelium (benign or malignant) that implants on the ovary is the source of low-grade and high-grade serous carcinoma rather than the ovarian surface epithelium as previously believed. Similarly, it is widely accepted that endometriosis is the precursor of endometrioid and clear cell carcinomas and as endometriosis is thought to develop from retrograde menstruation these tumors can also be regarded as involving the ovary secondarily. The origin of mucinous and transitional cell (Brenner) tumors is still not well established, although recent data suggest a possible origin from transitional epithelial nests located in paraovarian locations at the tubo-peritoneal junction. Thus, it now appears that type I and type II ovarian tumors develop independently along different molecular pathways, and that both types develop outside the ovary and involve it secondarily. If this concept is confirmed it leads to the conclusion that the only true primary ovarian neoplasms are gonadal stromal and germ cell tumors analogous to testicular tumors. This new paradigm of ovarian carcinogenesis has important clinical implications. By shifting the early events of ovarian carcinogenesis to the fallopian tube and endometrium instead of the ovary, prevention approaches, for example, salpingectomy with ovarian conservation, may play an important role in reducing the burden of ovarian cancer while preserving hormonal function and fertility.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Structure of Scientific Revolutions: 50th Anniversary Edition
Kuhn, T. S., & Hacking, I. (2012) · doi:10.7208/chicago/9780226458144.001.0001 · Cited by 21,170
The Structure of Scientific Revolutions
Kuhn, T. S. (1996) · doi:10.7208/chicago/9780226458106.001.0001 · Cited by 7,281
Rubin, M., & Stephen, C. D. (1993) · Cited by 3,149
Firminger, H. I. (1968) · Armed Forces Institute of Pathology eBooks · Cited by 3,044
Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279
International Histological Classification of Tumours
Weller, R. (1981) · Journal of Clinical Pathology · doi:10.1136/jcp.34.6.692-d · Cited by 2,042
The Origin and Pathogenesis of Epithelial Ovarian Cancer: A Proposed Unifying Theory
Kurman, R. J., & Shih, I.-M. (2010) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3181cf3d79 · Cited by 1,846
Self-citationBulun, S. E. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0804690 · Cited by 1,772
ARID1A Mutations in Endometriosis-Associated Ovarian Carcinomas
Wiegand, K. C., Shah, S. P., Al-Agha, O. M., Zhao, Y., Tse, K., Zeng, T., Senz, J., McConechy, M. K., Anglesio, M. S., Kalloger, S. E., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1008433 · Cited by 1,712
Self-citationTutt, A., Robson, M., Garber, J. E., Domchek, S. M., Audeh, M. W., Weitzel, J. N., Friedlander, M., Arun, B., Loman, N., Schmutzler, R. K., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60892-6 · Cited by 1,655
Blaustein's Pathology of the Female Genital Tract
(2019) · Springer eBooks · doi:10.1007/978-3-319-46334-6 · Cited by 1,335
Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma
Jones, S., Wang, T.-L., Shih, I.-M., Mao, T.-L., Nakayama, K., Roden, R., Glas, R., Slamon, D., Diaz, L. A., Vogelstein, B., et al. (2010) · Science · doi:10.1126/science.1196333 · Cited by 1,219
Self-citationShih, I.-M., & Kurman, R. J. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63708-x · Cited by 1,206
Self-citationKindelberger, D. W., Lee, Y., Miron, A., Hirsch, M. S., Feltmate, C., Medeiros, F., Callahan, M. J., Garner, E. O., Gordon, R. W., Birch, C., et al. (2007) · The American Journal of Surgical Pathology · doi:10.1097/01.pas.0000213335.40358.47 · Cited by 1,113
(2014) · African Studies Companion Online · doi:10.1163/1872-9037_afco_asc_2291 · Cited by 991
Ovarian cancer and hormone replacement therapy in the Million Women Study
Beral, V. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60534-0 · Cited by 937
Medeiros, F., Muto, M. G., Lee, Y., Elvin, J. A., Callahan, M. J., Feltmate, C., Garber, J. E., Cramer, D. W., & Crum, C. P. (2006) · American Journal of Surgical Pathology · doi:10.1097/01.pas.0000180854.28831.77 · Cited by 916
Mutation of the PIK3CA Gene in Ovarian and Breast Cancer
Campbell, I. G., Russell, S. E., Choong, D. Y. H., Montgomery, K. G., Ciavarella, M. L., Hooi, C. S. F., Cristiano, B. E., Pearson, R. B., & Phillips, W. A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2933 · Cited by 916
A candidate precursor to serous carcinoma that originates in the distal fallopian tube
Lee, Y., Miron, A., Drapkin, R., Nucci, M., Medeiros, F., Saleemuddin, A., Garber, J., Birch, C., Mou, H., Gordon, R., et al. (2007) · The Journal of Pathology · doi:10.1002/path.2091 · Cited by 898
Mutations in BRAF and KRAS Characterize the Development of Low-Grade Ovarian Serous Carcinoma
Singer, G., Oldt, R., Cohen, Y., Wang, B. G., Sidransky, D., Kurman, R. J., & Shih, I.-M. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.6.484 · Cited by 854
Self-citationPiek, J. M. J., van Diest, P. J., Zweemer, R. P., Jansen, J. W., Poort‐Keesom, R. J. J., Menko, F. H., Gille, J. J. P., Jongsma, A. P. M., Pals, G., Kenemans, P., et al. (2001) · The Journal of Pathology · doi:10.1002/path.1000 · Cited by 787
Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary
Ahmed, A. A., Etemadmoghadam, D., Temple, J., Lynch, A. G., Riad, M., Sharma, R., Stewart, C., Fereday, S., Caldas, C., deFazio, A., et al. (2010) · The Journal of Pathology · doi:10.1002/path.2696 · Cited by 787
Cho, K. R., & Shih, I.-M. (2009) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.4.110807.092246 · Cited by 694
Self-citationBlaustein’s Pathology of the Female Genital Tract
(2011) · Springer eBooks · doi:10.1007/978-1-4419-0489-8 · Cited by 668
Parker, W. H., Broder, M. S., Chang, E., Feskanich, D., Farquhar, C., Liu, Z., Shoupe, D., Berek, J. S., Hankinson, S., & Manson, J. E. (2009) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e3181a11c64 · Cited by 640
Callahan, M. J., Crum, C. P., Medeiros, F., Kindelberger, D. W., Elvin, J. A., Garber, J. E., Feltmate, C. M., Berkowitz, R. S., & Muto, M. G. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.2622 · Cited by 485
Konstantinopoulos, P. A., Spentzos, D., Karlan, B. Y., Taniguchi, T., Fountzilas, E., Francoeur, N., Levine, D. A., & Cannistra, S. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.5719 · Cited by 483
Wang, S. E., Narasanna, A., Perez-Torres, M., Xiang, B., Wu, F. Y., Yang, S., Carpenter, G., Gazdar, A. F., Muthuswamy, S. K., & Arteaga, C. L. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.05.023 · Cited by 470
Sato, N., Tsunoda, H., Nishida, M., Morishita, Y., Takimoto, Y., Kubo, T., & Noguchi, M. (2000) · PubMed · doi:10.11501/3187985 · Cited by 448
Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors.
OBATA, K., Morland, S. J., Watson, R. H., Hitchcock, A., Chenevix‐Trench, G., Thomas, E. J., & Campbell, I. (1998) · PubMed · Cited by 429
Are All Pelvic (Nonuterine) Serous Carcinomas of Tubal Origin?
Przybycin, C. G., Kurman, R. J., Ronnett, B. M., Shih, I.-M., & Vang, R. (2010) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3181ef7b16 · Cited by 410
Self-citationOrigins and molecular pathology of ovarian cancer
Bell, D. A. (2005) · Modern Pathology · doi:10.1016/s0893-3952(22)04456-8 · Cited by 387
Finch, A., Shaw, P., Rosen, B., Murphy, J., Narod, S. A., & Colgan, T. J. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2005.06.065 · Cited by 375
Colgan, T. J., Murphy, J., Cole, D. E. C., Narod, S., & Rosen, B. (2001) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200110000-00009 · Cited by 327
Epidemiology of Ovarian Cancer
Permuth-Wey, J., & Sellers, T. A. (2009) · Methods in Molecular Biology · doi:10.1007/978-1-60327-492-0_20 · Cited by 326
Bonome, T., Lee, J.-Y., Park, D.-C., Radonovich, M., Pise-Masison, C., Brady, J., Gardner, G. J., Hao, K., Wong, W. H., Barrett, J. C., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2240 · Cited by 319
Burks, R. T., Sherman, M. E., & Kurman, R. J. (1996) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199611000-00003 · Cited by 314
Self-citationWu, R., Hendrix-Lucas, N., Kuick, R., Zhai, Y., Schwartz, D. R., Akyol, A., Hanash, S., Misek, D. E., Katabuchi, H., Williams, B. O., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.02.016 · Cited by 313
Marquez, R. T., Baggerly, K. A., Patterson, A. P., Liu, J., Broaddus, R., Frumovitz, M., Atkinson, E. N., Smith, D. I., Hartmann, L., Fishman, D., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2509 · Cited by 308
Serous Carcinogenesis in the Fallopian Tube: A Descriptive Classification
Jarboe, E., Folkins, A., Nucci, M. R., Kindelberger, D., Drapkin, R., Miron, A., Lee, Y., & Crum, C. P. (2008) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0b013e31814b191f · Cited by 273
Salazar, H., Godwin, A. K., Daly, M. B., Laub, P. B., Hogan, W. M., Rosenblum, N., Boente, M. P., Lynch, H. T., & Hamilton, T. C. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.24.1810 · Cited by 264
Drew, Y., Mulligan, E. A., Vong, W.-T., Thomas, H. D., Kahn, S., Kyle, S., Mukhopadhyay, A., Los, G., Hostomsky, Z., Plummer, E. R., et al. (2011) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djq509 · Cited by 261
Riopel, M. A., Ronnett, B. M., & Kurman, R. J. (1999) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199906000-00001 · Cited by 258
Self-citationResults From Four Rounds of Ovarian Cancer Screening in a Randomized Trial
Partridge, E., Kreimer, A. R., Greenlee, R. T., Williams, C., Xu, J.-L., Church, T. R., Kessel, B., Johnson, C. C., Weissfeld, J. L., Isaacs, C., et al. (2009) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e31819cda77 · Cited by 258
Histological Typing of Ovarian Tumours
Osborn, R. A. (1975) · Pathology · doi:10.1016/s0031-3025(16)38968-1 · Cited by 250
Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy.
Mok, S. C., Bell, D. A., KNAPP, R. C., Fishbaugh, P. M., Welch, W. R., Muto, M. G., Berkowitz, R. S., & Tsao, S. (1993) · PubMed · Cited by 237
In ovarian neoplasms, BRAF , but not KRAS , mutations are restricted to low‐grade serous tumours
Sieben, N. L., Macropoulos, P., Roemen, G. M., Kolkman‐Uljee, S. M., Jan Fleuren, G., Houmadi, R., Diss, T., Warren, B., Al Adnani, M., de Goeij, A. P., et al. (2004) · The Journal of Pathology · doi:10.1002/path.1521 · Cited by 237
Mayr, D., Hirschmann, A., Löhrs, U., & Diebold, J. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2006.05.029 · Cited by 224
β-Catenin Expression Pattern in Stage I and II Ovarian Carcinomas
Gamallo, C., Palacios, J., Moreno, G., Calvo de Mora, J., Suárez, A., & Armas, A. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65148-6 · Cited by 220
Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma
Gemignani, M. L., Schlaerth, A. C., Bogomolniy, F., Barakat, R. R., Lin, O., Soslow, R., Venkatraman, E., & Boyd, J. (2003) · Gynecologic Oncology · doi:10.1016/s0090-8258(03)00264-6 · Cited by 213
Allelotyping of endometriosis with adjacent ovarian carcinoma reveals evidence of a common lineage.
Jiang, X., Morland, S. J., Hitchcock, A., Thomas, E. J., & Campbell, I. (1998) · PubMed · Cited by 207
Mutations of BRAF and KRAS Precede the Development of Ovarian Serous Borderline Tumors
Ho, C.-L., Kurman, R. J., Dehari, R., Wang, T.-L., & Shih, I.-M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2067 · Cited by 206
Self-citationMeinhold-Heerlein, I., Bauerschlag, D., Hilpert, F., Dimitrov, P., Sapinoso, L. M., Orlowska-Volk, M., Bauknecht, T., Park, T.-W., Jonat, W., Jacobsen, A., et al. (2005) · Oncogene · doi:10.1038/sj.onc.1208298 · Cited by 205
The Fallopian Tube: Primary Site of Most Pelvic High-grade Serous Carcinomas
Salvador, S., Gilks, B., Köbel, M., Huntsman, D., Rosen, B., & Miller, D. (2009) · International Journal of Gynecological Cancer · doi:10.1111/igc.0b013e318199009c · Cited by 203
Rutgers, J. L., & Scully, R. E. (1988) · Cancer · doi:10.1002/1097-0142(19880115)61:2<340::aid-cncr2820610225>3.0.co;2-u · Cited by 198
Paley, P. J., Swisher, E. M., Garcia, R. L., Agoff, S. N., Greer, B. E., Peters, K. L., & Goff, B. A. (2001) · Gynecologic Oncology · doi:10.1006/gyno.2000.6071 · Cited by 189
Saegusa, M., & Okayasu, I. (2001) · The Journal of Pathology · doi:10.1002/path.856 · Cited by 188
Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms
Nakayama, K., Nakayama, N., Kurman, R. J., Cope, L., Pohl, G., Samuels, Y., Velculescu, V. E., Wang, T.-L., & Shih, I.-M. (2006) · Cancer Biology & Therapy · doi:10.4161/cbt.5.7.2751 · Cited by 187
Self-citationCatasús, L., Bussaglia, E., Rodrı́guez, I., Gallardo, A., Pons, C., Irving, J. A., & Prat, J. (2004) · Human Pathology · doi:10.1016/j.humpath.2004.07.019 · Cited by 181
Plante, M., Rubin, S. C., Wong, G. Y., Federici, M. G., Finstad, C. L., & Gastl, G. A. (1994) · Cancer · doi:10.1002/1097-0142(19940401)73:7<1859::aid-cncr2820730714>3.0.co;2-l · Cited by 177
Seidman, J. D., & Khedmati, F. (2008) · Archives of Pathology & Laboratory Medicine · doi:10.5858/132.11.1753 · Cited by 168
Dehari, R., Kurman, R. J., Logani, S., & Shih, I. (2007) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31802cbbe9 · Cited by 168
Self-citationSurface Epithelial Tumors of the Ovary
Seidman, J. D., Cho, K. R., Ronnett, B. M., & Kurman, R. J. (2010) · Springer eBooks · doi:10.1007/978-1-4419-0489-8_14 · Cited by 168
Self-citationKuhn, E., Meeker, A. K., Wang, T., Sehdev, A. E. S., Kurman, R. J., & Shih, I. (2010) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3181dcede7 · Cited by 154
Self-citationAmplicon profiles in ovarian serous carcinomas
Nakayama, K., Nakayama, N., Jinawath, N., Salani, R., Kurman, R. J., Shih, I., & Wang, T. (2007) · International Journal of Cancer · doi:10.1002/ijc.22609 · Cited by 152
Self-citationVeras, E. F. T., Mao, T., Ayhan, A., Ueda, S. M., Lai, H. C., Hayran, M., Shih, I., & Kurman, R. J. (2009) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31819c4271 · Cited by 151
Self-citationCharacterization of Active Mitogen-Activated Protein Kinase in Ovarian Serous Carcinomas
Hsu, C., Bristow, R. E., Cha, M. S., Wang, B. G., Ho, C., Kurman, R. J., Wang, T., & Shih, I. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0893 · Cited by 148
Self-citationBRCA1/2-related ovarian cancers are of tubal origin: a hypothesis
Piek, J. M. J., Verheijen, R. H. M., Kenemans, P., Massuger, L. F. A. G., Bulten, H., & van Diest, P. J. (2003) · Gynecologic Oncology · doi:10.1016/s0090-8258(03)00365-2 · Cited by 147
Rosenblatt, K. A., & Thomas, D. B. (1996) · PubMed · Cited by 145
Ichikawa, Y., Nishida, M., Suzuki, H., Yoshida, S., Tsunoda, H., Kubo, T., Uchida, K., & Miwa, M. (1994) · PubMed · Cited by 144
EVENTS OF REPRODUCTIVE LIFE AND THE INCIDENCE OF EPITHELIAL OVARIAN CANCER
Risch, H. A., Weiss, N. S., Lyon, J. L., Daling, J. R., & Liff, J. M. (1983) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a113523 · Cited by 143
Carcangiu, M. L., Radice, P., Manoukian, S., Spatti, G., Gobbo, M., Pensotti, V., Crucianelli, R., & Pasini, B. (2003) · International Journal of Gynecological Pathology · doi:10.1097/01.pgp.0000101082.35393.84 · Cited by 136
Alternate molecular genetic pathways in ovarian carcinomas of common histological types
Willner, J. B., Wurz, K., Allison, K. H., Galic, V., Garcia, R. L., Goff, B. A., & Swisher, E. M. (2007) · Human Pathology · doi:10.1016/j.humpath.2006.10.007 · Cited by 135
PRIMARY CARCINOMA OF THE FALLOPIAN TUBE
Sedlis, A. (1961) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-196104000-00022 · Cited by 131
Gilks, C. B., Vanderhyden, B. C., Zhu, S., van de Rijn, M., & Longacre, T. A. (2004) · Gynecologic Oncology · doi:10.1016/j.ygyno.2004.11.039 · Cited by 116
Genetic Analysis of the Early Natural History of Epithelial Ovarian Carcinoma
Pothuri, B., Leitão, M. M., Levine, D. A., Viale, A. J., Olshen, A. B., Arroyo, C. D., Bogomolniy, F., Olvera, N., Lin, O., Soslow, R. A., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010358 · Cited by 113
Werness, B. A., Afify, A. M., Bielat, K. L., Eltabbakh, G. H., Piver, M. S., & Paterson, J. M. (1999) · Human Pathology · doi:10.1016/s0046-8177(99)90269-1 · Cited by 113
The Fallopian Tube-Peritoneal Junction
Seidman, J. D., Yemelyanova, A. V., Zaino, R. J., et al. (2010) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0b013e3181f29d2a · Cited by 106
Sehdev, A. E. S., Kurman, R. J., Kuhn, E., & Shih, I. (2010) · Modern Pathology · doi:10.1038/modpathol.2010.60 · Cited by 95
Self-citationStratton, J. F., BUCKLEY, C. H., Lowe, D., & Ponder, B. A. J. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.7.626 · Cited by 91
May, T., Virtanen, C., Sharma, M., Milea, A. L., Begley, H., Rosen, B. P., Murphy, K. J., Brown, T. J., & Shaw, P. A. (2010) · Gynecologic Oncology · doi:10.1016/j.ygyno.2010.01.006 · Cited by 72
Yang, D., Smith, E. R., Cohen, C., Wu, H., Patriotis, C., Godwin, A. K., Hamilton, T. C., & Xu, X. (2002) · Cancer · doi:10.1002/cncr.10497 · Cited by 67
Shih, I., Chen, L., Wang, C., Gu, J., Davidson, B., Cope, L., Kurman, R. J., Xuan, J., & Wang, T. (2010) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2010.08.003 · Cited by 67
Self-citationStaebler, A., Heselmeyer‐Haddad, K., Bell, K. A., Riopel, M. A., Perlman, E. J., Ried, T., & Kurman, R. J. (2002) · Human Pathology · doi:10.1053/hupa.2002.30212 · Cited by 52
Self-citationMicropapillary serous carcinoma of the ovary
Alli, P. M., & Ali, S. Z. (2002) · Cancer · doi:10.1002/cncr.10619 · Cited by 48
Kuhn, E., Meeker, A. K., Visvanathan, K., Gross, A. L., Wang, T., Kurman, R. J., & Shih, I. (2011) · Modern Pathology · doi:10.1038/modpathol.2011.67 · Cited by 35
Self-citationA critical re-appraisal of BRCA1 methylation studies in ovarian cancer
Senturk, E., Cohen, S., Dottino, P., & Martignetti, J. A. (2010) · Gynecologic Oncology · doi:10.1016/j.ygyno.2010.07.026 · Cited by 33
Cai, K. Q., Wu, H. G., Klein–Szanto, A. J., & Xu, X. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2009.03.023 · Cited by 17
(2000) · doi:10.1002/1097-0142(20000715)89:2
Cited by
Lin, J. S., Bowles, E. J. A., Williams, S. B., & Morrison, C. C. (2017) · JAMA · doi:10.1001/jama.2017.0562 · Cited by 1,082
A clinically applicable molecular-based classification for endometrial cancers
Talhouk, A., McConechy, M. K., Leung, S., Li-Chang, H. H., Kwon, J. S., Melnyk, N., Yang, W., Senz, J., Boyd, N., Karnezis, A. N., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.190 · Cited by 971
Pearce, C. L., Templeman, C., Rossing, M. A., Lee, A., Near, A. M., Webb, P. M., Nagle, C. M., Doherty, J. A., Cushing-Haugen, K. L., Wicklund, K. G., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70404-1 · Cited by 939
An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity
Kopper, O., de Witte, C. J., Lõhmussaar, K., Valle-Inclan, J. E., Hami, N., Kester, L., Balgobind, A. V., Korving, J., Proost, N., Begthel, H., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0422-6 · Cited by 834
High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints
Lisio, M.-A., Fu, L., Goyeneche, A., Gao, Z.-H., & Telleria, C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20040952 · Cited by 680
Metadata
- Authors
- Kurman, R. J., & Shih, I.-M.
- Venue
- Human Pathology
- Publisher
- Elsevier BV
- Published
- 2011-07
- Volume
- 42
- Issue
- 7
- Pages
- 918-931
- ISSN
- 0046-8177 (ISSN-L)
- OpenAlex
- W1974756790
- Cited by
- 1,073
- References
- 89
- FWCI
- 103.09
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.